Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials The Lancet Oncology in conversation with

Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00040-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncTell us what you thought about this episode by sending us a text messageContinue this conversation on social!Follow us toda...